Telix to Showcase New ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline at EANM

Melbourne (Australia) | 6 September 2023

Telix today announces presentations featuring the Company’s theranostic programs at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in Vienna from 9 – 13 September 2023.

Further data from Telix’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) ( Identifier: NCT03849118) will be presented in on oral session on Sunday 10 September.

In addition, the congress program features the following Telix initiatives:

  • Sponsored symposium on personalised diagnostics in urological cancers: the promise of nuclear medicine;
  • Phase III ProstACT GLOBAL study of TLX591 investigational prostate cancer therapy;
  • Artificial intelligence (AI) Segmentation and primary characterisation of prostate cancer lesions using models trained on 68Ga‑PSMA‑11 image datasets;
  • Nobody Left Behind (NOBLE) Registry of Telix’s single photon emission computed tomography (SPECT)-based prostate cancer imaging agent TLX599-CDx;[1] and,
  • A preclinical evaluation of carbonic anhydrase IX- (CAIX)-targeted lutetium-177 radionuclide therapy in combination with immune checkpoint inhibition.

Dr Colin Hayward, Telix Chief Medical Officer, said, “We are pleased to be so well represented at this year’s EANM Annual Congress, with a sponsored symposium and abstracts accepted across Telix’s late-stage prostate and kidney cancer imaging and therapy programs. In addition, our innovations in AI and quantum computing for prostate cancer segmentation and characterisation will be featured in an oral presentation.

“Once again, we will be supporting the EANM Sanjiv Sam Gambhir Young Investigator Award, an exciting opportunity for a junior physician or scientist to further develop their career in radiopharmaceuticals. We look forward to seeing you at booth number 241 to discuss Telix’s industry leading theranostic pipeline and opportunities for collaboration.”

EANM presentation details are as follows:

Sponsored Symposium: Personalised diagnostics in urological cancers: the promise of nuclear medicine

  • Chairperson: Professor Stefano Fanti, Director of Nuclear Medicine Division and of PET Unit – Policlinico S.Orsola, Bologna, Italy
  • Introduction: How PSMA PET dusted off the Management of Prostate Cancer.
    • Professor Stefano Fanti.
  • Prostate Cancer Imaging: is there only one PSMA-PET?.
    • Dr. Macarena Rodríguez Fraile, Nuclear Medicine Clínica Universidad de Navarra, Pamplona, Spain
  • Next Generation Imaging in Urology: What’s new in Bladder and Kidney Cancers.
    • Prof. dr. Karolien Goffin, Nuclear Medicine, University Hospital Leuven – KU Leuven, Leuven, Belgium.
  • The Use of Artificial Intelligence in Prostate Cancer Management.
    • Dr. László Papp, Center for Medical Physics and Biomedical Engineering (CMPBME), Medical University of Vienna, Vienna, Austria.

Date & Time: Sunday, 10 September, 2023, 1:15 – 2:45 PM (CEST).

Session: Theranostics Track – Oncology & Theranostics Committee / EARL – Featured Session: Old but Novel Techniques

Title: 89Zr-DFO-girentuximab PET/CT imaging for clear cell renal cell carcinoma – ZIRCON study results of diagnostic performance, including in very small lesions (oral presentation)

Date and Time: 10-Sep-23, 4:20 – 4:30 PM

Presenter: Clement Bailly, Nantes University Hospital, Nantes, FRANCE

Presentation ID: OP-194

Session: Cutting Edge Science Track – TROP Session: Segmentation and Denoising

Title: Using a 3-D UNet artificial intelligence model to segment PSMA-avid lesions in 68Ga‑PSMA‑11 PET/CT images (top-rated oral presentation)

Date and Time: 10-Sep-23, 4:55 – 5:05 PM

Presenter: Simon Wail, Telix Pharmaceuticals, North Melbourne, AUSTRALIA

Presentation ID: OP-222

Session: M2M Track – TROP Session: TME and Therapy: Direct Targeting and Secondary Effects

Title: Evaluation of Therapeutic and Immunological Action of CAIX-Targeted Lutetium-177 Radionuclide Therapy Combined with Immune Checkpoint Inhibition (top-rated oral presentation)

Date and Time: 11-Sep-23, 10:15 – 10:25 AM

Presenter: Simone Kleinendorst, Department of Medical Imaging, Radboud University Medical Center, Nijmegen, NETHERLANDS

Presentation ID: OP-358

Session: Clinical Oncology Track – TROP Session: Prostate Cancer Biochemical Recurrence 

Title: The imaging characteristics of theranostic 99mTc/188Re-PSMA-GCK01 is equivalent to dedicated diagnostic 99mTc-HYNIC-iPSMA in prostate cancer (top-rated oral presentation) 

Date and Time: 11-Sep-23, 6:05 – 6:15 PM 

Presenter: Eduards Mamlins, Department of Nuclear Medicine, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Duesseldorf, GERMANY 

Presentation ID: OP-512 

Session: e-Poster Presentations Session 10 – Oncology & Theranostics Committee: Haematological and Abdominal Malignancies / localised Treatments

Title: NOBLE (Nobody Left Behind) Registry: Initial Experience of [99mTc]-HYNIC-iPSMA Imaging in the Detection of Prostate Cancer (oral e-poster presentation)

Date and Time: 12-Sep-23, 10:53 – 10:57 AM

Presenter: Fuad Novruzov, Department of Nuclear Medicine Azerbaijan National Centre of Oncology, Baku AZERBAIJAN

Presentation ID: EPS-206

Session: Cutting Edge Science Track – TROP Session: AI Methods and Applications  

Title: Primary prostate characterization in PSMA-11 PET on real quantum computers (top-rated oral presentation) 

Date and Time: 12-Sep-23, 3:00 – 3:10 PM 

Presenter: Laszlo Papp, Medical University of Vienna, Vienna, AUSTRIA 

Presentation ID: OP-706 

Session: Clinical Oncology Track – TROP Session: Prostate Cancer Treatment

Title: ProstACT GLOBAL: A Phase 3 Study of 177Lu-DOTA-rosopatamab (TLX591) With and Without the Best Standard of Care for Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer Progressing Despite Prior Treatment with a Novel Androgen Axis Drug (top-rated oral presentation)

Date and Time: 12-Sep-23, 3:30 – 3:40 PM

Presenter: Neel Patel, Telix Pharmaceuticals, North Melbourne, AUSTRALIA

Presentation ID: OP-718

Session: D: Technical Studies -> D5 Radiopharmacy/ Radiochemistry -> D57 Radiopharmaceutical Preparation and Quality Control

Title: The Optimization of the Current ININ Method of Lu-177-DOTA-HYNIC-iPSMA (e-poster)

Presenter: Yehia Omar, Misr Radiology Center, Cairo, EGYPT

Presentation ID: EP-0880

To read the full media release click here

[1] A collaboration with the Oncidium Foundation.